ADTX: Aditxt, Inc. Stock

by  •  • Comments Off on ADTX: Aditxt, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.22
Enterprise Value ($M) 10.62
Book Value ($M) 4.45
Book Value / Share 0.31
Price / Book 0.50
NCAV ($M) -23.30
NCAV / Share -1.64
Price / NCAV -0.10

Profitability (mra)
Return on Invested Capital (ROIC) -2.73
Return on Assets (ROA) -0.90
Return on Equity (ROE) -2.50

Liquidity (mrq)
Quick Ratio 0.08
Current Ratio 0.09

Balance Sheet (mrq) ($M)
Current Assets 2.09
Assets 29.84
Liabilities 25.39
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A CVI Investments, Inc. 0.50
02-06 13G/A Intracoastal Capital, Llc 1.50
2024-01-02 13G/A Sabby Management, Llc 4.99 -94.70

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-18 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-15 59,552,709 158,295,338 37.62
2025-01-14 4,704,519 14,143,068 33.26
2025-01-13 6,886,183 22,166,976 31.07
2025-01-10 2,802,968 9,063,582 30.93

(click for more detail)

Similar Companies
ACHV – Achieve Life Sciences, Inc. ACXP – Acurx Pharmaceuticals, Inc.
ADIL – Adial Pharmaceuticals, Inc. ADVM – Adverum Biotechnologies, Inc.
AGEN – Agenus Inc.


Financial data and stock pages provided by
Fintel.io